Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Astria Therapeutics, Inc. is a biopharmaceutical company developing novel monoclonal antibody therapies for allergic and immunological diseases. Its lead candidates include navenibart, a plasma kallikrein inhibitor for hereditary angioedema (HAE), and STAR-0310, an OX40 antagonist for atopic dermatitis (AD). Astria focuses on long-acting, patient-friendly treatments targeting unmet medical needs, leveraging validated mechanisms and third-party manufacturing to serve global specialty markets.
This description was generated via AI from an annual report. Updated about 1 year ago.